Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases.

Hormone Therapy for Cancer is a Risk Factor for Relapse of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Jul 11;: Authors: Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S, New York Crohn’s and Colitis Organization (NYCCO) Abstract BACKGROUND & AIMS: Exposure to hormone contraception has been associated with an increased risk of relapse of inflammatory bowel diseases (IBD). Little is known about…

Read More

Corrigendum to Age-Related Survival Differences in Patients With Inflammatory Bowel Disease-Associated Colorectal Cancer: A Population-Based Cohort Study.

Corrigendum to Age-Related Survival Differences in Patients With Inflammatory Bowel Disease-Associated Colorectal Cancer: A Population-Based Cohort Study. Inflamm Bowel Dis. 2019 Jul 13;: Authors: PMID: 31301139 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31301139?dopt=Abstract

Read More

Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer.

Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer. Inflamm Bowel Dis. 2019 Jul 09;: Authors: Yao D, Dong M, Dai C, Wu S Abstract Dysregulated inflammatory responses play a pivotal role in the initiation, development, and progression of tumors, as demonstrated by the association between ulcerative colitis and the increased risk of colon carcinoma. In this review, the underlying mechanisms for the initiation and development of ulcerative colitis and colitis-associated cancer are described, mainly focusing on the inflammation and inflammatory cytokine.…

Read More

Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.

Related Articles Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. Lancet Gastroenterol Hepatol. 2019 Jun 10;: Authors: Schreuders EH, Grobbee EJ, Nieuwenburg SAV, Kapidzic A, van Roon AHC, van Vuuren AJ, Lansdorp-Vogelaar I, Spijker WWJ, Izelaar K, Bruno MJ, Kuipers EJ, Spaander MCW Abstract BACKGROUND: Faecal immunochemical test (FIT)-based colorectal cancer screening requires successive rounds for maximum preventive effect. Advanced neoplasia can bleed intermittently and thus might be missed by single faecal sampling. Few studies have been done on two sample…

Read More

Epidemiology of Colorectal Cancer in Average Risk Adults 20-39 Years of Age: A Population-Based National Study.

Related Articles Epidemiology of Colorectal Cancer in Average Risk Adults 20-39 Years of Age: A Population-Based National Study. Dig Dis Sci. 2019 Jun 07;: Authors: Glover M, Mansoor E, Panhwar M, Parasa S, Cooper GS Abstract BACKGROUND/AIMS: While overall rates of colorectal cancer (CRC) have declined in individuals aged above 50 years of age, this decline has not been seen in younger individuals who do not benefit from current screening guidelines. We sought to describe the prevalence of CRC in adults 20-39 years of age without family history of CRC or inflammatory bowel…

Read More

Role of Lymphatic Deficiency in the Pathogenesis and Progression of Inflammatory Bowel Disease to Colorectal Cancer in an Experimental Mouse Model.

Role of Lymphatic Deficiency in the Pathogenesis and Progression of Inflammatory Bowel Disease to Colorectal Cancer in an Experimental Mouse Model. Inflamm Bowel Dis. 2019 Jun 07;: Authors: Daley SK, Witte MH, Washington J, Bernas M, Kiela P, Thorn J, Tanoue N, Alexander JS Abstract BACKGROUND: Inflammatory bowel disease (IBD) is characterized by chronic inflammation, which can progress to colorectal cancer, with duration of disease being the most important risk factor. Although many factors are involved, the pathogenic link between inflammation and cancer and the role played by the lymphatic…

Read More

Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer.

Related Articles Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated cancer. J Crohns Colitis. 2019 Jun 05;: Authors: Yang M, Zhang F, Yang C, Wang L, Sung J, Garg P, Zhang M, Merlin D Abstract BACKGROUND AND AIMS: Heat shock protein 90 (Hsp90)-targeted therapy has been proposed as a promising strategy for the treatment of ulcerative colitis (UC) and colitis-associated cancer (CAC). The systemic administration of the Hsp90 inhibitor, 17-AAG, was found to be profoundly protective…

Read More

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn’s Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. J Crohns Colitis. 2019 May 22;: Authors: Smeets FGM, Liedorp PR, van der Poel M, Miclea RL, Masclee AAM, Pierik M Abstract Use of ustekinumab in Crohn’s disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn’s disease, who developed an anaplastic large cell T cell…

Read More

Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers.

Related Articles Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. Am J Gastroenterol. 2019 May;114(5):771-776 Authors: Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez JM, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert JP, Domènech E, ENEIDA registry by GETECCU Abstract OBJECTIVES: Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses…

Read More

The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study.

Related Articles The incidence of cancer and mortality in paediatric onset inflammatory bowel disease in Denmark and Finland during a 23-year period: a population-based study. Aliment Pharmacol Ther. 2019 May 08;: Authors: Malham M, Jakobsen C, Paerregaard A, Virta LJ, Kolho KL, Wewer V Abstract BACKGROUND: Recent studies report increased risks of both cancer and mortality in paediatric onset inflammatory bowel disease (pIBD) but the reproducibility of this is unknown. AIM: In this population-based study we aim to estimate the risk of cancer and mortality in the Danish and Finnish…

Read More
<< Go Back